Investigational Drug Information for LOU064
✉ Email this page to a colleague
What is the development status for investigational drug LOU064?
LOU064 is an investigational drug.
There have been 17 clinical trials for LOU064.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 15th 2021.
The most common disease conditions in clinical trials are Urticaria, Chronic Urticaria, and Sclerosis. The leading clinical trial sponsors are Novartis Pharmaceuticals and [disabled in preview].
There are eleven US patents protecting this investigational drug and two hundred and thirty-nine international patents.
Summary for LOU064
| US Patents | 11 |
| International Patents | 239 |
| US Patent Applications | 96 |
| WIPO Patent Applications | 47 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2021-12-15) |
| Vendors | 35 |
Recent Clinical Trials for LOU064
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines | Novartis Pharmaceuticals | Phase 3 |
| A Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo and With Omalizumab as Active Control in CSU Adult Patients. | Novartis Pharmaceuticals | Phase 3 |
| 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Y | Novartis Pharmaceuticals | Phase 3 |
Clinical Trial Summary for LOU064
Top disease conditions for LOU064
Top clinical trial sponsors for LOU064
US Patents for LOU064
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| LOU064 | ⤷ Sign Up | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | ⤷ Sign Up |
| LOU064 | ⤷ Sign Up | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | ⤷ Sign Up |
| LOU064 | ⤷ Sign Up | Treatment of cancer using a CLL-1 chimeric antigen receptor | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | ⤷ Sign Up |
| LOU064 | ⤷ Sign Up | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for LOU064
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| LOU064 | Argentina | AR102035 | 2034-07-21 | ⤷ Sign Up |
| LOU064 | Australia | AU2015292744 | 2034-07-21 | ⤷ Sign Up |
| LOU064 | Australia | AU2020202726 | 2034-07-21 | ⤷ Sign Up |
| LOU064 | Brazil | BR112017001183 | 2034-07-21 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
